Abstract

BackgroundCarbapenem non-susceptible Citrobacter sp. (CNSC) are becoming increasingly recognized as healthcare-associated (HA) pathogens, but data on clinical and molecular epidemiology, species diversity and mechanisms of carbapenem resistance are lacking.MethodsWe reviewed patients at University of Pittsburgh Medical Center with CNSC positive cultures from 2000 to 2018. The diversity of CNSC species among a subset of isolates from all UPMC sites was confirmed by 16S rRNA typing, and the presence of carbapenemase enzymes in the same isolates was determined by PCR amplificon. Minimum inhibitory concentrations (MICs) were determined by broth microdilution. Significance of epidemiological trends over time was determined by linear regression, and correlation with antibiotic consumption was determined by cross-correlation using STATA v15.ResultsBetween 2000 and 2018, 3% (78/2817) of all Citrobacter sp. were CNS. CNSC rates increased from 4% in 2000 to 10% in 2018 (R2 = 0.206, P = 0.05), as did carbapenem consumption (6.5–34.5 DDDs/1000, R2 = 0.831, P < 0.001) (Figure 1). Twenty-one isolates from 19 patients were available for additional analysis. Patients had multiple comorbidities (84%), frequently acquired CNSC in the healthcare setting (84%), were colonized with other organisms (68%), and had high rates of in-hospital mortality/discharge to hospice (47%) (Table 1). C. freundii was the dominant species identified (16/21), followed by C. farmeri (2/21), C. koseri (2/21), and C. werkmanii (1/21). Carbapenemases were identified in 14 isolates, including KPC (n = 12), NDM (n = 2), and OXA-48 (n = 1) (Table 2). Isolates were frequently susceptible to ceftazidime–avibactam (MIC median [IQR]: 2[0.5,8]) 81%) and meropenem-vaborbactam (86%) (MIC median [IQR] 0.12[0.3,0.5]) (Table 2).ConclusionCNSC species are diverse, have emerged as an HA pathogen at our center, and cause high rates of mortality. Further studies, including ongoing genome sequencing and analysis, are required to better elucidate CNSC diversity and resistance mechanisms. Disclosures All authors: No reported disclosures.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.